PFIZER INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1849-01-01
- Employees
- 88K
- Market Cap
- $163.3B
- Website
- http://www.pfizer.com
Safety and Efficacy of Lorbrena
- Conditions
- Non-small Cell Lung Cancer
- First Posted Date
- 2019-02-18
- Last Posted Date
- 2023-12-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 683
- Registration Number
- NCT03844464
- Locations
- 🇯🇵
3-22-7, Yoyogi, Shibuya-ku, Tokyo, Japan
Prevalence and Characteristics of Transthyretin Amyloidosis in Patients With Left Ventricular Hypertrophy of Unknown Etiology
- Conditions
- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)
- Interventions
- Diagnostic Test: Diagnosis of TTR amyloidosis cardiomyopathy
- First Posted Date
- 2019-02-15
- Last Posted Date
- 2024-02-12
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 812
- Registration Number
- NCT03842163
- Locations
- 🇵🇹
Centro Hospitalar e Universitario de Coimbra, Coimbra, Portugal
🇸🇮University Medical Centre Ljubljana - Department of Cardiology, Ljubljana, Slovenia
🇫🇷CHU de Nantes, Nantes cedex 1, France
Trial to Evaluate the Safety and Immunogenicity of a 20-Valent Pneumococcal Vaccine in Adults 65 Years of Age or Older With Prior Pneumococcal Vaccination
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: PPSV23Biological: 20vPnCBiological: 13vPnC
- First Posted Date
- 2019-02-11
- Last Posted Date
- 2021-02-21
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 875
- Registration Number
- NCT03835975
- Locations
- 🇺🇸
East Valley Gastroenterology and Hepatology Associates, Chandler, Arizona, United States
🇺🇸The Pain Center of Arizona, Phoenix, Arizona, United States
🇺🇸Meridian Clinical Research, LLC, Norfolk, Nebraska, United States
Patient Perception of Treatment Burden in Weekly Versus Daily Growth Hormone Injections in Children With GHD
- First Posted Date
- 2019-02-06
- Last Posted Date
- 2021-10-14
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 87
- Registration Number
- NCT03831880
- Locations
- 🇺🇸
Hackensack University Medical Center, Hackensack, New Jersey, United States
🇸🇰Národný ústav detských chorôb, Detská klinika, Bratislava, Slovakia
🇺🇸Shriners Hospitals for Children, Tampa, Florida, United States
Trial to Evaluate the Safety and Immunogenicity of 3 Lots of 20-valent Pneumococcal Conjugate Vaccine in Pneumococcal Vaccine-Naïve Adults
- Conditions
- Pneumococcal Disease
- Interventions
- Biological: 13vPnCBiological: 20vPnC
- First Posted Date
- 2019-02-04
- Last Posted Date
- 2020-11-23
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 1710
- Registration Number
- NCT03828617
- Locations
- 🇺🇸
Anaheim Clinical Trials, LLC, Anaheim, California, United States
🇺🇸Accel Research Sites - Clinical Research Unit, DeLand, Florida, United States
🇺🇸Meridian Clinical Research, LLC, Dakota Dunes, South Dakota, United States
A DRUG-DRUG INTERACTION STUDY BETWEEN PF-06650833 AND PF-06651600 FOLLOWING MULTIPLE DOSES IN HEALTHY PARTICIPANTS
- Conditions
- Healthy
- Interventions
- First Posted Date
- 2019-02-01
- Last Posted Date
- 2020-05-20
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 15
- Registration Number
- NCT03827668
- Locations
- 🇺🇸
Pfizer New Haven Clinical Research Unit, New Haven, Connecticut, United States
Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single-Dose of PF-06651600 in Healthy Participants
- Conditions
- Healthy Participants
- Interventions
- Drug: PF-06651600 10 mg tabletsDrug: Itraconazole Solution 200 mg
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2019-06-28
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03821493
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Be-bru, Belgium
Diflucan Bioequivalence Study For Transferring The Manufacture
- Conditions
- Bioequivalence
- Interventions
- Drug: Reference drugDrug: Test drug
- First Posted Date
- 2019-01-29
- Last Posted Date
- 2021-07-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 28
- Registration Number
- NCT03821480
- Locations
- 🇰🇷
Chungnam National University Hospital, Clinical Trials Center, Daejeon, Korea, Republic of
A Study of Adverse Events and Suspected Adverse Drug Reactions of Patients Under Treatment of Apixaban for Venous Thomboembolism (VTE) Treatment
- Conditions
- Thrombosis, Deep VeinPulmonary Embolism
- First Posted Date
- 2019-01-23
- Last Posted Date
- 2021-11-11
- Lead Sponsor
- Pfizer
- Registration Number
- NCT03812835
Study of PF-04965842 Effect on Rosuvastatin Pharmacokinetics in Healthy Participants
- First Posted Date
- 2019-01-16
- Last Posted Date
- 2019-05-06
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 12
- Registration Number
- NCT03806101
- Locations
- 🇧🇪
Pfizer Clinical Research Unit, Brussels, Belgium